Piper Sandler downgraded Optinose (OPTN) to Neutral from Overweight with a $9 price target after Paratek Pharmaceuticals announced it will be acquiring the company for $9 per share up front and contingent value rights worth up to $5 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue